UniversityLibraryCurrent studentsStaff intranet
University of Sydney
University of Sydney
View Item 
  • Sydney eScholarship Home
  • Postgraduate Theses
  • Sydney Digital Theses (University of Sydney Access only)
  • View Item
  • Sydney eScholarship Home
  • Postgraduate Theses
  • Sydney Digital Theses (University of Sydney Access only)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Production of Menaquinone-7 for Food and Pharmaceutical Applications

Thumbnail
View/Open
Thesis (PDF, 6.84MB)
Date
2018-10-05
Author
Ma, Yanwei
Metadata
Show full item record
Abstract
Vitamin K has emerged as a multi-functional vitamin that is essential in a diverse range of physiological effects in the human body. Among all the vitamin K family members, menaquinone-7 (vitamin K2) has gained the most popularity for the prevention and treatment of osteoporosis and atherosclerosis. The aim of this study was to develop a strategy to produce high level of MK-7 via fermentation by Bacillus subtilis for applications in the food and pharmaceutical industries. A series of screening and optimisation steps were carried out to develop a viable MK-7 formula for fortified food application. The highest titre of 30 mg/L MK-7 was achieved by using 10 w/v % soy protein and 5 w/v% glycerol supplemented with 0.5 w/v % yeast extract and 0.6 % K2HPO4.The major problem of foam formation in stirred fermenter was tackled by using a novel strategy of controlled dual feeding of glycerol and soy protein simultaneously. The MK-7 concentration in the fermentation was increased by four fold, from 30 mg/L in a 100 mL shake flask to 112 mg/L in a 2 L fed-batch bioreactor. Metabolic engineering was another approach undertaken to increase MK-7 production. 12 engineered B. subtilis 168 strains were constructed by individually overexpressing or co-overexpressing the rate limiting MEP pathway genes dxs, dxr, idi and the downstream gene menA in different orders. An ordered overexpression of menA-dxs-dxr-idi produced the highest titre of MK-7 at 50 mg/L in 50 mL SYG media in shake flasks. This improvement was 11-fold higher than the B. subtilis 168 control strain (4.5 mg/L) and 2.2-fold higher than the best-performing B. subtilis natto strain (22 mg/L). In summary, the MK-7 production was significantly increased by process optimisation and metabolic engineering strategies in this study. This study also implies the potential of using B. subtilis as the cellular factory for production of other industrially important MEP pathway derived molecules.
URI
http://hdl.handle.net/2123/20877
Collections
  • Sydney Digital Theses (University of Sydney Access only) [2933]

Browse

All of Sydney eScholarshipCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister

Statistics

Most Popular ItemsStatistics by CountryMost Popular Authors

Links

University homeLibraryCurrent studentsStaff intranet

Repository

  • About us
  • FAQ
  • Policies & guidelines
  • Email us
  • Non-UniKey login
Leadership for good starts here

Media

  • News
  • Find an expert
  • Media contacts

Student links

  • Log in to University systems
  • Study dates
  • Student handbooks
  • Timetables
  • Library

About us

  • Our world rankings
  • Faculties and schools
  • Centres and institutes
  • Campus locations
  • Maps and locations

Connect

  • Contact us
  • Find a staff member
  • Careers at Sydney
  • Events
  • Emergencies and personal safety
Inspired: Campaign to support the University of SydneyGroup of Eight
Disclaimer
Privacy
Accessibility
Website feedback
ABN: 15 211 513 464
CRICOS Number: 00026A
Disclaimer
Privacy
Accessibility
Website feedback
ABN: 15 211 513 464
CRICOS Number: 00026A